Small Molecules that Modify RNA Expression

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that modify RNA expression, targeting some of the world's most intractable diseases

LEARN MORE

OUR PARTNERS

LATEST SKYHAWK NEWS

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR® platform.SKY-0515’s Phase 1 study will inc

Drugging RNA

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success. Companies differ...

Drugging RNA with Pills : Small Molecules for a Big Frontier

Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets? Infused...

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

Paul Schloesser – Associate Editor, Endpoints A heavily financed biotech looking to drug RNA with small molecules is adding yet another...

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Nicole DeFeudis – Editor, Endpoints A few years after becoming one of the first major biotechs out to drug RNA with small molecules,...

OUR PARTNERS

LATEST SKYHAWK NEWS

WHAT WE DO

ONCOLOGY

NEUROLOGY

INFLAMMATORY INFECTIOUS RARE

NEUROMUSCULAR & METABOLIC